Parnax Lab

Parnax Lab FCF Conversion

The FCF Conversion Rate (FCF/EBITDA) of Parnax Lab (506128.BO) as of Nov 14, 2026 is 119.14 %. In the previous year, FCF Conversion Rate (FCF/EBITDA) was -172.93 % — a change of -168.89% (higher).

FCF Conversion

119.14 %

YoY

-168.89%

Last updated:

FCF Conversion Rate (FCF/EBITDA) of Parnax Lab is 2025 119.14 % . FCF Conversion Rate (FCF/EBITDA) of Parnax Lab was 2024 -172.93 % . It decreases by -168.89% higher compared to the previous year.

The Parnax Lab FCF Conversion history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF Conversion
Date
FCF Conversion
Jan 1, 2018
726.18 INR
Jan 1, 2019
-78.97 INR
Jan 1, 2020
152.21 INR
Jan 1, 2021
63.52 INR
Jan 1, 2022
-112.61 INR
Jan 1, 2023
111.74 INR
Jan 1, 2024
-172.93 INR
Jan 1, 2025
119.14 INR
The Parnax Lab FCF Conversion history
YEARFCF ConversionYoY
119.14 %-168.89%
-172.93 %-254.77%
111.74 %-199.23%
-112.61 %-277.28%
63.52 %-58.27%
152.21 %-292.75%
-78.97 %-110.87%
726.18 %+3,588.37%
19.69 %-118.67%
-105.47 %+10.97%
-95.04 %-59.05%
-232.09 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Parnax Lab Stock analysis

What does Parnax Lab do? Parnax Lab Ltd. generates revenue through manufacturing and exporting pharmaceutical formulations, including cough expectorants, antacids, anti-histamines, multi-vitamins, enzyme preparations, pediatric formulations, geriatric special formulations, highly viscous products, and suspensions. The company trades pharmaceuticals and medicinal products, focusing on high-volume oral formulations for diverse consumer segments. Naxpar Pharma Private Limited serves as its subsidiary in these operations. The firm's primary customers are likely healthcare providers, pharmacies, and distributors within the pharmaceutical industry, though specific buyer details are not disclosed. Parnax Lab Ltd. operates through the pharmaceutical formulations segment, emphasizing export-driven manufacturing and trading activities. Its product portfolio targets various health needs, from pediatric to geriatric care, with a strong focus on oral delivery systems. Parnax Lab is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Parnax Lab stock

FCF Conversion Rate (FCF/EBITDA) of Parnax Lab is 119.14 % in 2025.

FCF Conversion Rate (FCF/EBITDA) of Parnax Lab changed from -172.93 % to 119.14 %, representing a -168.89% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of FCF Conversion Rate (FCF/EBITDA) Parnax Lab since 2006 – with annual values, charts, and detailed analysis.

FCF conversion measures how effectively EBITDA converts to free cash flow. Higher conversion indicates efficient capital allocation and low maintenance costs.

A 'good' varies by industry and company stage. On Eulerpool, you can compare FCF Conversion Rate (FCF/EBITDA)'s Parnax Lab with sector peers and the industry average to assess whether it is attractive.

To evaluate FCF Conversion Rate (FCF/EBITDA)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for FCF Conversion Rate (FCF/EBITDA).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — Parnax Lab

All Key Metrics — Parnax Lab